Literature DB >> 7781863

Hormone replacement therapy: compliance and cost after screening for osteoporosis.

D J Torgerson1, C Donaldson, I T Russell, D M Reid.   

Abstract

OBJECTIVE: To assess HRT compliance and cost 1 year after population screening for low bone density.
DESIGN: Postal questionnaire sent out to women 1 year after having a bone density scan. MAIN OUTCOME MEASURES: Compliance with HRT, type of HRT and cost.
RESULTS: Compliance with HRT after screening for women with low bone density was 48% for postmenopausal women and 59% for women with a simple hysterectomy. The most often used form of HRT was Estraderm (49%) for women with a hysterectomy, whilst for women with an intact uterus Prempak-C (54%) was the most popular. The average annual cost of treating women who had had a hysterectomy was 67 pounds whilst for women with an intact uterus it was 61 pounds, a non-significant difference.
CONCLUSIONS: Approximately 50% of women with low bone density had started HRT within 1 year of having a densitometry examination. Previous reports of the cost advantage of treating women who had had a hysterectomy relative to those who had not has been overstated.

Entities:  

Mesh:

Year:  1995        PMID: 7781863     DOI: 10.1016/0028-2243(94)02002-v

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  11 in total

1.  Developing a policy on osteoporosis. Bone densitometry is worth while.

Authors:  D J Torgerson
Journal:  BMJ       Date:  1996-05-11

2.  Economic impact of tibolone compared with continuous-combined hormone replacement therapy. In the management of postmenopausal women with climacteric symptoms in the UK.

Authors:  J M Plumb; J F Guest
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

3.  The pharmacoeconomics of hormone replacement therapy.

Authors:  D J Torgerson; D M Reid
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

4.  Department of Health shoots itself in the hip. Why the report of the Advisory Group on Osteoporosis undermines evidence based purchasing.

Authors:  T A Sheldon; A Raffle; I Watt
Journal:  BMJ       Date:  1996-02-03

5.  Initiation of hormone replacement therapy after diagnosis of osteoporosis by bone densitometry.

Authors:  G Phillipov; E Mos; S Scinto; P J Phillips
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 6.  Raloxifene: a review of its use in postmenopausal osteoporosis.

Authors:  D Clemett; C M Spencer
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

7.  Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995.

Authors:  M T Connelly; M Richardson; R Platt
Journal:  J Gen Intern Med       Date:  2000-08       Impact factor: 5.128

8.  Factors related to the use of bone densitometry: survey responses of 494 primary care physicians in New England.

Authors:  D H Solomon; M T Connelly; C J Rosen; B Dawson-Hughes; D P Kiel; S L Greenspan; E S Leib; M Holick; A H Miguel; J S Finkelstein
Journal:  Osteoporos Int       Date:  2003-03-14       Impact factor: 4.507

9.  A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study.

Authors:  L Shepstone; R Fordham; E Lenaghan; I Harvey; C Cooper; N Gittoes; A Heawood; T J Peters; T O'Neill; D Torgerson; R Holland; A Howe; T Marshall; J A Kanis; E McCloskey
Journal:  Osteoporos Int       Date:  2012-10       Impact factor: 4.507

10.  Bone mineral density measurements: are they worth while?

Authors:  D J Torgerson; C Donaldson; D M Reid
Journal:  J R Soc Med       Date:  1996-08       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.